Duality Biotherapeutics, Inc. in 1 story
The narratives 9606.HK currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
9606.HK in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Its next-generation antibody-drug conjugates are directly exposed to strong global licensing demand.
Bear side
0 storiesNo bear-side stories for 9606.HK yet.